Blood-Brain Barrier Penetration of Therapeutic Agents in Human

Summary

This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.

Timeline

Start

2020-10-29

Primary completion

2021-02-23

Completion

2021-02-23

Drugs

Indications